Literature DB >> 31625881

[Diagnostic and Therapeutic Challenges in Atypical Hemolytic Uremic Syndrome: A Case Report].

Sofia Reis1, Daniela Ramos2, Carolina Cordinhã3, Clara Gomes3.   

Abstract

The atypical hemolytic uremic syndrome comprises a thrombotic microangiopathy resulting from the complement alternate pathway hyperactivation. Its severity requires early diagnosis and treatment. The differential diagnosis includes typical hemolytic uremic syndrome (associated with Shiga toxin) and thrombotic thrombocytopenic purpura (associated with deficient activity of ADAMTS13). The only specific treatment currently available for atypical hemolytic uremic syndrome is eculizumab. We describe the case of a child with atypical hemolytic uremic syndrome diagnosed in the context of bloody diarrhea, complicated by neurological involvement that posed several diagnostic and therapeutic challenges.

Entities:  

Keywords:  Atypical Hemolytic Uremic Syndrome; Eculizumab

Mesh:

Substances:

Year:  2019        PMID: 31625881     DOI: 10.20344/amp.10021

Source DB:  PubMed          Journal:  Acta Med Port        ISSN: 0870-399X


  1 in total

1.  The Importance of Eculizumab in the Treatment of Atypical Hemolytic Uremic Syndrome.

Authors:  Mariana S Santos; Sofia Ventura; Abel Alves; Raquel Cabral; Manuela Henriques
Journal:  Cureus       Date:  2022-06-08
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.